Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Pipeline Review, H1 2018
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Pipeline Review, H1 2018
SUMMARY
According to the recently published report 'Methionine Aminopeptidase 2 - Pipeline Review, H1 2018'; Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Methionine aminopeptidase 2 is an enzyme that in humans is encoded by the METAP2 gene. Methionine aminopeptidase 2 is a member of the dimetallohydrolase family is a cytosolic metalloenzyme that catalyzes the hydrolytic removal of N-terminal methionine residues from nascent proteins. Increased expression of this METAP2 is associated with various forms of cancer, and the anti-cancer drugs fumagillin and ovalicin inhibit the protein by irreversibly binding to its active site. Inhibitors of METAP2 have shown to be effective for the treatment of obesity.
The report 'Methionine Aminopeptidase 2 - Pipeline Review, H1 2018' outlays comprehensive information on the Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Metabolic Disorders, Oncology, Genetic Disorders and Ophthalmology which include indications Obesity, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Prader-Willi Syndrome (PWS), Prostate Cancer, Solid Tumor, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Prostate Cancer, Osteosarcoma, Type 2 Diabetes and Uveitis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Methionine Aminopeptidase 2 - Pipeline Review, H1 2018'; Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Methionine aminopeptidase 2 is an enzyme that in humans is encoded by the METAP2 gene. Methionine aminopeptidase 2 is a member of the dimetallohydrolase family is a cytosolic metalloenzyme that catalyzes the hydrolytic removal of N-terminal methionine residues from nascent proteins. Increased expression of this METAP2 is associated with various forms of cancer, and the anti-cancer drugs fumagillin and ovalicin inhibit the protein by irreversibly binding to its active site. Inhibitors of METAP2 have shown to be effective for the treatment of obesity.
The report 'Methionine Aminopeptidase 2 - Pipeline Review, H1 2018' outlays comprehensive information on the Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Metabolic Disorders, Oncology, Genetic Disorders and Ophthalmology which include indications Obesity, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Prader-Willi Syndrome (PWS), Prostate Cancer, Solid Tumor, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Prostate Cancer, Osteosarcoma, Type 2 Diabetes and Uveitis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18)
- The report reviews Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics and enlists all their major and minor projects
- The report assesses Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Overview
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Companies Involved in Therapeutics Development
Asieris Pharmaceuticals Co Ltd
Chong Kun Dang Pharmaceutical Corp
Merck KGaA
SynDevRx Inc
Takeda Pharmaceutical Co Ltd
Zafgen Inc
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Drug Profiles
APL-1301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
beloranib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fumagillin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lodamin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-8891 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitroxoline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RSF-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDX-7195 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDX-7320 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MAP2 for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MetAP2 for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZGN-1061 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZGN-1258 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Dormant Products
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Discontinued Products
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Product Development Milestones
Featured News & Press Releases
Mar 06, 2018: Zafgen Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes
Jan 05, 2018: Zafgen Provides Update on its Obesity Drug candidate ZGN-1061
Jan 05, 2018: Zafgen Provides update on its Drug Candidate ZGN-1258
Sep 12, 2017: Zafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
Sep 12, 2017: Zafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes
Aug 24, 2017: Asieris Pharmaceuticals Invited to Present at the 20th Annual Meeting of CSCO
Jun 10, 2017: Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association's 77th Annual Scientific Sessions
Jun 06, 2017: Zafgen to Present Two Late-Breaking Abstracts for ZGN-1061 at the American Diabetes Association 77th Scientific Sessions
May 31, 2017: Asieris Pharmaceuticals Presents at the 2017 ChinaBio Partnering Forum
May 04, 2017: Zafgen Announces Positive Top line Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor
Mar 30, 2017: Asieris announces first patient in APL-1202 pivotal trial
Mar 09, 2017: Zafgen Provides Update on ZGN-1061
Feb 26, 2017: Asieris announces initiation of APL-1202 pivotal clinical trial
Sep 20, 2016: Zafgen Initiates Multiple Ascending Dose Cohorts in Phase 1 Clinical Trial of ZGN-1061
Jul 19, 2016: Zafgen Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Overview
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Companies Involved in Therapeutics Development
Asieris Pharmaceuticals Co Ltd
Chong Kun Dang Pharmaceutical Corp
Merck KGaA
SynDevRx Inc
Takeda Pharmaceutical Co Ltd
Zafgen Inc
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Drug Profiles
APL-1301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
beloranib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fumagillin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lodamin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-8891 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitroxoline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RSF-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDX-7195 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SDX-7320 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MAP2 for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MetAP2 for Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZGN-1061 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZGN-1258 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Dormant Products
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Discontinued Products
Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Product Development Milestones
Featured News & Press Releases
Mar 06, 2018: Zafgen Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes
Jan 05, 2018: Zafgen Provides Update on its Obesity Drug candidate ZGN-1061
Jan 05, 2018: Zafgen Provides update on its Drug Candidate ZGN-1258
Sep 12, 2017: Zafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
Sep 12, 2017: Zafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes
Aug 24, 2017: Asieris Pharmaceuticals Invited to Present at the 20th Annual Meeting of CSCO
Jun 10, 2017: Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association's 77th Annual Scientific Sessions
Jun 06, 2017: Zafgen to Present Two Late-Breaking Abstracts for ZGN-1061 at the American Diabetes Association 77th Scientific Sessions
May 31, 2017: Asieris Pharmaceuticals Presents at the 2017 ChinaBio Partnering Forum
May 04, 2017: Zafgen Announces Positive Top line Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor
Mar 30, 2017: Asieris announces first patient in APL-1202 pivotal trial
Mar 09, 2017: Zafgen Provides Update on ZGN-1061
Feb 26, 2017: Asieris announces initiation of APL-1202 pivotal clinical trial
Sep 20, 2016: Zafgen Initiates Multiple Ascending Dose Cohorts in Phase 1 Clinical Trial of ZGN-1061
Jul 19, 2016: Zafgen Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Asieris Pharmaceuticals Co Ltd, H1 2018
Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
Pipeline by Merck KGaA, H1 2018
Pipeline by SynDevRx Inc, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Pipeline by Zafgen Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Asieris Pharmaceuticals Co Ltd, H1 2018
Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
Pipeline by Merck KGaA, H1 2018
Pipeline by SynDevRx Inc, H1 2018
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Pipeline by Zafgen Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
COMPANIES MENTIONED
Asieris Pharmaceuticals Co Ltd
Chong Kun Dang Pharmaceutical Corp
Merck KGaA
SynDevRx Inc
Takeda Pharmaceutical Co Ltd
Zafgen Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
COMPANIES MENTIONED
Asieris Pharmaceuticals Co Ltd
Chong Kun Dang Pharmaceutical Corp
Merck KGaA
SynDevRx Inc
Takeda Pharmaceutical Co Ltd
Zafgen Inc
